[Increased renal prostaglandin E2 secretion in Bartter's syndrome].
In a 52-year-old patient with Bartter's syndrome, peripheral venous prostaglandin E2 (PGE2) and plasma renin activity (PRA) levels were markedly elevated and plasma aldosterone concentration (pa) was at the upper limit of normal, though inappropriately high relative to the decreased plasma and whole body potassium levels. Blood pressure, plasma volume, exchangeable body sodium, plasma cortisol and urinary catecholamines were normal. Renal venous PGE2 was two to three times higher than peripheral PGE2. Indomethacin (300 mg/day) decreased peripheral PGE2 by 50%, PRA by 84% and PA by 72%, induced a positive potassium balance (greater than 350 mEq) with normal plasma potassium levels, and returned the previously marked resistance to the pressor effect of angiotensin II to normal. During the entire study, highly significant correlations (p less than 0.001) between peripheral PGE2 and PRA (r = 0.86) or PA (r = 0.90) were found. In this patient the hyperreninemia was not related to volume depletion. These data indicate that in Bartter's syndrome renal PGE2 secretion may be increased, systemic blood levels of PGE2 may be elevated and closely related to PRA, and indomethacin ameliorates these abnormalities and improves potassium balance. These results are consistent with the ascription of an important role to excessive renal PGE2 secretion in the pathogenesis of Bartter's syndrome.
D000450:Aldosterone / Q000097:blood; D001477:Bartter Syndrome / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D006929:Hyperaldosteronism / Q000378:metabolism*; D007213:Indomethacin / Q000627:therapeutic use; D007668:Kidney / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011458:Prostaglandins E / Q000378:metabolism*; D012083:Renin / Q000097:blood
D011458:Prostaglandins E; D000450:Aldosterone; D012083:Renin; D011188:Potassium; D007213:Indomethacin
Erhöhte renale Prostaglandin-E2-Sekretion bei Bartter-Syndrom.